Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third,

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also being trialled in other cancers.

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more likely to still be alive two years after treatment.

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the disease returning by a third...